$75MSeries B, 19 February 2026
Series B led by Forbion to fund a Phase 2b trial of vapendavir in COPD.
- Amount
- $75M
- Stage
- Series B
- Announced
- 19 February 2026
- Lead
- Forbion
- Other investors
- Sanofi, Medicxi, Pitango, Atlantic Partners
- Use of funds
- Series B led by Forbion to fund a Phase 2b trial of vapendavir in COPD.
- Checked
- Announced by the company
- Source
- Altesa BioSciences closes oversubscribed $75M Series B prnewswire.com